CRIS Current Research Information System

CECI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.331
AS - Asia 5.710
EU - Europa 3.753
AF - Africa 356
SA - Sud America 328
Continente sconosciuto - Info sul continente non disponibili 305
OC - Oceania 11
AN - Antartide 1
Totale 16.795
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.226
VN - Vietnam 1.736
SG - Singapore 1.469
CN - Cina 1.247
GB - Regno Unito 922
IT - Italia 747
DE - Germania 467
HK - Hong Kong 433
SE - Svezia 421
FR - Francia 267
IN - India 251
BR - Brasile 229
RU - Federazione Russa 228
IE - Irlanda 145
BD - Bangladesh 118
ZA - Sudafrica 113
NL - Olanda 101
FI - Finlandia 96
KR - Corea 95
TG - Togo 86
JP - Giappone 80
EE - Estonia 74
CA - Canada 70
CI - Costa d'Avorio 70
JO - Giordania 65
CH - Svizzera 57
UA - Ucraina 48
AR - Argentina 44
BG - Bulgaria 40
SC - Seychelles 30
BE - Belgio 29
IR - Iran 27
TH - Thailandia 27
ID - Indonesia 26
PL - Polonia 23
ES - Italia 22
NG - Nigeria 22
AT - Austria 20
EC - Ecuador 20
MX - Messico 20
PH - Filippine 20
IQ - Iraq 16
TR - Turchia 16
TW - Taiwan 15
SA - Arabia Saudita 11
CL - Cile 10
PK - Pakistan 10
AU - Australia 9
MY - Malesia 9
UZ - Uzbekistan 9
CO - Colombia 8
LT - Lituania 8
RO - Romania 8
VE - Venezuela 8
CR - Costa Rica 6
EG - Egitto 6
ET - Etiopia 6
AL - Albania 5
KZ - Kazakistan 5
MA - Marocco 5
CZ - Repubblica Ceca 4
GR - Grecia 4
LB - Libano 4
PT - Portogallo 4
TN - Tunisia 4
DK - Danimarca 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GA - Gabon 2
KE - Kenya 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
AQ - Antartide 1
BB - Barbados 1
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MU - Mauritius 1
Totale 16.481
Salva come PNG Salva come JPEG
Città #
Singapore 1.026
Southend 826
Ashburn 697
Fairfield 605
Hong Kong 412
Chandler 405
San Jose 352
Santa Clara 289
Ho Chi Minh City 278
Seattle 274
Houston 268
Wilmington 266
Woodbridge 259
Hanoi 238
Cambridge 229
Princeton 184
Beijing 166
Hefei 162
Dublin 145
Council Bluffs 137
Bologna 135
Ann Arbor 133
Dong Ket 124
Lauterbourg 113
Boardman 109
Los Angeles 108
New York 94
Westminster 90
Lomé 86
Helsinki 83
Nanjing 73
Seoul 73
Berlin 71
Abidjan 70
Padova 68
Amman 64
Milan 60
Tokyo 59
Dallas 55
Redondo Beach 51
Da Nang 46
Bern 45
Buffalo 43
Jinan 42
Shenyang 40
São Paulo 40
Haiphong 39
Munich 39
Sofia 36
Florence 34
Rome 34
Turin 34
Saint Petersburg 33
San Diego 32
Guangzhou 31
Changsha 30
Medford 30
Frankfurt am Main 29
Toronto 29
Brussels 27
Hebei 27
Nanchang 27
Johannesburg 26
Bremen 25
Redwood City 23
Tianjin 22
Chicago 21
London 21
Nuremberg 21
Abeokuta 20
Orem 20
Zhengzhou 20
Phoenix 19
Bengaluru 17
San Francisco 17
Norwalk 16
Atlanta 15
Biên Hòa 15
Brooklyn 15
Amsterdam 14
Dearborn 14
Jiaxing 14
Mumbai 14
Warsaw 14
Yubileyny 14
Falkenstein 13
Shanghai 13
Falls Church 12
Taiyuan 12
The Dalles 12
Thái Bình 12
Vienna 12
Des Moines 11
Montreal 11
Shenzhen 11
Taizhou 11
Baghdad 10
Hangzhou 10
Jakarta 10
Naples 10
Totale 10.291
Salva come PNG Salva come JPEG
Nome #
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 355
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence 272
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 236
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml 231
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 231
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 231
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 230
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 225
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 222
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 217
11C-Choline PET/CT for Restaging of Bladder Cancer 217
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 214
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 212
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 209
68Ga-PSMA PET/CT for restaging prostate cancer after definitive therapy: Results of a prospective single-center trial 208
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 202
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and midterm follow-up 199
18f-fdg pet/ct for restaging gastric cancer after surgical resection 196
68Ga-PSMA PET/CT in prostate cancer 195
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 194
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. 192
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 192
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 192
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 191
18F-FACBC PET/CT in comparison to 11c-choline for the detection of prostate cancer relapse after radical prostatectomy: A perspective study in 50 patients 187
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 185
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 185
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 184
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 177
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 177
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment 176
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 175
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications 171
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 171
PET/CT and prostate cancer 170
18F-FACBC PET/CT VS. 11C-CHOLINE FOR THE DETECTION OF PROSTATE CANCER RELAPSE AFTER RADICAL TREATMENT 167
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 166
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 165
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 165
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 164
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 164
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT IN COMPARISON WITH CONTRASTENHANCED CT IN THE PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER USING THE PATHOLOGICAL SPECIMENS AS REFERENCE STANDARD 163
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 161
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 161
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 161
DIAGNOSTIC ACCURACY OF 11C-CHOLINE PET/CT COMPARED TO CONTRASTENHANCED CT IN THE POSTOPERATIVE RESTAGING OF RECURRENT BLADDER CANCER: ANALYSIS OF 20 CONSECUTIVE PATIENTS 160
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 157
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. 156
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 152
New radiopharmaceutical markers for metabolism and receptor 152
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 152
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. 152
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 152
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 151
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. 150
Role of 11C-Choline PET/CT in androgen sensitive prostate cancer patients treated with intermittent ADT: A sequential PET/CT study after therapy interruption 149
IL RUOLO DELLA 11C-COLINA PET/CT IN PAZIENTI CON RECIDIVA BIOCHIMICA DOPO PROSTATECTOMIA RADICALE E CARCINOMA PROSTATICO ORMONO-RESISTENTE SOTTOPOSTI A TERAPIA DI DEPRIVAZIONE ANDROGENICA 148
Yttrium 90 Intra Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5 Year Experience at a Single Center 148
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. 146
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 143
Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: preliminary results 143
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis 142
PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT? 141
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. 137
68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report 137
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68 Ga-PSMA-11 PET/CT 136
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study 136
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 135
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. 134
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 132
Role of 18F-FDG PET/CT in the restaging of patients affected by clear cell renal carcinoma 131
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. 130
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. 130
Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. 129
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. 128
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings. 126
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer 125
New aspects of molecular imaging in prostate cancer. 125
Molecular Imaging and Precision Medicine in Prostate Cancer 124
PET/CT in prostate cancer 123
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. 122
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 120
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 120
null 119
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 118
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 114
null 113
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 113
Therapy assessment in prostate cancer using choline and PSMA PET/CT. 112
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 111
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy 111
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 110
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial 110
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography. 103
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence 102
PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an "EMBARK-Like" cohort 102
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 101
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 95
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer 94
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 90
Totale 15.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.251
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.251
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.429 0 58 97 126 170 78 49 114 62 59 357 259
2022/20231.949 172 288 112 254 115 133 50 103 386 89 145 102
2023/2024555 75 85 26 54 39 90 30 34 22 42 29 29
2024/20252.341 114 344 173 187 430 151 131 49 24 122 108 508
2025/20265.397 482 398 418 361 577 269 503 232 1.137 505 285 230
2026/2027436 222 214 0 0 0 0 0 0 0 0 0 0
Totale 16.795